home All News open_in_new Full Article

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease  Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded […]


today 8 h. ago attach_file Economics

attach_file Sport
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Other
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Society
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Culture


ID: 4289452886
Add Watch Country

arrow_drop_down